Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment

Information

  • Research Project
  • 9324105
  • ApplicationId
    9324105
  • Core Project Number
    SB1AG034714
  • Full Project Number
    5SB1AG034714-07
  • Serial Number
    034714
  • FOA Number
    PAR-16-027
  • Sub Project Id
  • Project Start Date
    9/1/2009 - 16 years ago
  • Project End Date
    5/31/2018 - 7 years ago
  • Program Officer Name
    SALIVE, MARCEL
  • Budget Start Date
    7/1/2017 - 8 years ago
  • Budget End Date
    5/31/2018 - 7 years ago
  • Fiscal Year
    2017
  • Support Year
    07
  • Suffix
  • Award Notice Date
    6/27/2017 - 8 years ago

Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment

Pelvic organ prolapse (POP) is a highly prevalent condition affecting over 50% of women in the US during their lifetimes. Urinary incontinence (UI) affects an estimated 38% of women. Both POP and UI are more common in women than in men and their prevalence is increased with age. Some loss of utero-vaginal support occurs in most adult women, however, the true etiology of prolapse and differences seen among individuals are not entirely understood. Changes in the elasticity of the vaginal walls, connective support tissues and muscle function are thought to be significant factors in the development of the diseased conditions. There is a strong need in pelvic floor structure and functional imaging to be integrated into mainstream diagnostics in obstetrics, gynecology and urogynecology. This integration will facilitate communications between different specialties and has the potential to greatly improve the multidisciplinary management of complex pelvic floor disorders. In the Phases I-IIB of this project, we developed an innovative approach and the device,/ Vaginal Tactile Imager (VTI), completed clinical studies, received an FDA approval for the core technology, and established manufacturing and distribution partnership with Advanced Tactile Imaging (www.tactile-imaging.com). These were the critical steps that significantly reduced number of project risk factors. However, crossing the ?Valley of Death? to make this innovative device commercially successful, requires additional support in technical assistance as well as in later stage research and development. We identified and proposed how to overcome four critical barriers to commercial success: 1) need for reimbursement / CPT codes, 2) high manufacturing cost, 3) additional clinical evidence of VTI capabilities in diagnosis and aid for choice of applied treatment, and 4) FDA clearance for clinically relevant Indication for Use. Removing these obstacles would lead to clinical acceptance and market penetration of this new technology.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    SB1
  • Administering IC
    AG
  • Application Type
    5
  • Direct Cost Amount
    409184
  • Indirect Cost Amount
    159076
  • Total Cost
    608038
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:608038\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARTANN LABORATORIES, INC.
  • Organization Department
  • Organization DUNS
    959147026
  • Organization City
    TRENTON
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    086181414
  • Organization District
    UNITED STATES